A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

OBJECTIVE: This 24‐week, phase IIb, double‐blind study was undertaken to evaluate the efficacy and safety of mavrilimumab (a monoclonal antibody to granulocyte–macrophage colony‐stimulating factor receptor α) and golimumab (a monoclonal antibody to tumor necrosis factor [anti‐TNF]) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinblatt, Michael E., McInnes, Iain B., Kremer, Joel M., Miranda, Pedro, Vencovsky, Jiri, Guo, Xiang, White, Wendy I., Ryan, Patricia C., Godwood, Alex, Albulescu, Marius, Close, David, Burmester, Gerd R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767745/
https://www.ncbi.nlm.nih.gov/pubmed/28941039
http://dx.doi.org/10.1002/art.40323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767745/
https://www.ncbi.nlm.nih.gov/pubmed/28941039
http://dx.doi.org/10.1002/art.40323

Ejemplares similares